March 18, 2026

Imperative Care’s Stroke and Vascular Thrombectomy Portfolio Supported by New Financing

March 18, 2026—Imperative Care, Inc., a developer of treatments for thromboembolic disease, announced the closing of a $100 million convertible note financing.

According to the company, the proceeds from the financing will support the continued commercialization of Imperative Care’s stroke and vascular thrombectomy portfolios. Proceeds will also be used for investments in next-generation and new product development—including the Telos robotic platform—as well as clinical evidence generation to further demonstrate the impact of these technologies on patient outcomes.

Imperative Care stated that the financing round was led by new investors Elevage Medical Technologies and Perceptive Advisors in partnership with existing investor Catalio Capital Management, LP. Additionally, new investors Longaeva Partners LP and Brown Advisory participated in the financing. The round was supported by Imperative Care’s existing investors, including Ally Bridge Group and Bain Capital Life Sciences.

Imperative Care also announced the appointment of Evan Melrose, MD, CEO of Elevage Medical Technologies, to its Board of Directors.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

March 18, 2026

Imperative Care’s Stroke and Vascular Thrombectomy Portfolio Supported by New Financing

Current Issue

Keep In Touch